Key result
In a 44-year-old male with Erdheim-Chester disease and pulmonary arterial hypertension, dabrafenib treatment improved respiratory symptoms and facial xanthomas, though cystic lung changes progressed.
Why the study?
Erdheim-Chester disease involves multiple systems with non-specific pulmonary manifestations, making diagnosis challenging.
Case Report (n=1)
This case report documents the first known instance of pulmonary hypertension associated with Erdheim-Chester disease, expanding the known complications of this rare condition.
Cystic lung lesions may indicate ECD; extends recognized pulmonary phenotype but remains hypothesis-generating.
BACKGROUND: Erdheim-Chester disease (ECD), a rare type of non-Langerhans cell histiocytosis, was classified as a haematopoietic tumour by the World Health Organization (WHO) in 2016. It involves multiple systems and is challenging to diagnose due to its broad spectrum of clinical manifestations. The pulmonary manifestations of ECD lack specificity. We present a case of ECD with pronounced cystic lung abnormalities to increase awareness of the disease among pulmonologists and expedite diagnosis and treatment. CASE PRESENTATION: We report the case of a 44-year-old male who presented with intermittent fever, cough, bilateral leg pain, extensive xanthomas on his face, and extensive pulmonary cystic changes noted on imaging following a pulmonary stab wound incident. Thoracoabdominal enhanced computed tomography (CT) revealed progressive cystic changes in the lungs, notably in the upper lungs and subpleural areas; thickened interlobular septa; circumferential wall thickening of the left subclavian artery; uneven thickening of the aortic wall; and soft tissue shadows in the right atrium of the heart. Bone scintigraphy revealed bilateral symmetric long-bone uptake. Despite his advanced lung abnormalities, he exhibited no hypoxia. Notably, echocardiography indicated severe pulmonary artery hypertension, and right heart catheterization confirmed increased mean pulmonary artery pressure at 37 mmHg and elevated pulmonary vascular resistance. Pathology examination of transbronchial lung biopsy and the facial xanthomas confirmed the presence of ECD-characteristic histiocytes, and genetic testing revealed a BRAF V600E mutation. Treatment with dabrafenib improved respiratory symptoms and facial xanthomas, although some symptoms persisted. Follow-up CT showed reduced interstitial lesions but more pronounced cystic changes. CONCLUSIONS: This case of ECD illustrates rare pulmonary cystic changes alongside pulmonary arterial hypertension, challenging typical presentations of ECD. This is the first documented instance of pulmonary hypertension associated with ECD, broadening the understanding of its potential complications. These findings emphasize the need for considering ECD in the differential diagnosis of atypical cystic lung lesions, especially when accompanied by systemic symptoms such as xanthomas and bone pain.
No takes yet. Share an insight, caveat, or question.
Yuxi et al. (2025) conducted a case report in Erdheim-Chester disease (n=1). Dabrafenib was evaluated on Clinical and radiological response. In a 44-year-old male with Erdheim-Chester disease and pulmonary arterial hypertension, dabrafenib treatment improved respiratory symptoms and facial xanthomas, though cystic lung changes progressed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: